Leder av Pediatric Follow-up Group ved Universitetet i Bergen og Klinisk forskningspost for barn og unge ved Haukeland universitetssykehus.

Hennes forskning er spesielt fokusert på nyremedisin, immunologi og kliniske utprøvingsstudier. Som del av NorCRIN (siden 2012) og NorPedMed (siden 2014) jobber hun for mer behandlingsforskning gjennomført i Norge. Hun er ECRINs norske vitenskapelige representant, leder barnenefrologisk interessegruppe i NBF og er nasjonal ESPN-kontakt.

Leder for undervisning, Klinisk institutt 2, Universitetet i Bergen

MED9: Pediatrisk nefrologi og reumatologi. Pediatrisk farmakologi. Generell pediatri. Væskebehandling hos barn. Forgiftninger hos barn. Sosialpediatri.

MED5: Kommunikasjon med barn og ungdom

GCP901: Kursleder. Kurs i kliniske utprøvingsstudier.

MEDMET1: ICH-Good Clinical Practice

NUCLI352: Pediatrisk nefrologi

 

Vitenskapelig artikkel

• Tøndel, Camilla; Jenum, Synne; Tonby, Kristian et al. (2026). SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. (ekstern lenke)
• Bredholt, Geir; Sævik, Marianne; Søyland, Hanne et al. (2024). Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults. (ekstern lenke)
• Burlina, Alessandro; Duning, Thomas; Fernandez-Martin, Julian et al. (2024). Fabry disease: current gaps and actionable solutions to improve Fabry patients’ clinical journey. (ekstern lenke)
• Holida, Myrl; Linhart, Aleš; Pisani, Antonio et al. (2024). A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. (ekstern lenke)
• Zhou, Fan; Vahokoski, Juha; Øyen, Siri et al. (2024). Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection. (ekstern lenke)
• Hopkin, Robert J.; Martins, Ana; Alton, Julia et al. (2024). Plain Language Summary: Looking at treatment outcomes in people with Fabry disease who started agalsidase beta before the age of 30 years. (ekstern lenke)
• Hansen, Lena; Brokstad, Karl Albert; Bansal, Amit et al. (2023). Durable immune responses after BNT162b2 vaccination in home-dwelling old adults. (ekstern lenke)
• Bradley, John S; Makieieva, Nataliia; Tøndel, Camilla et al. (2023). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial. (ekstern lenke)
• Wallace, Eric; Goker-Alpan, Ozlem; Wilcox, William R et al. (2023). Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: Results from the 2-year randomised phase III BALANCE study. (ekstern lenke)
• Elsaid, Hassan Osman Alhassan; Rivedal, Mariell Lossius; Skandalou, Eleni et al. (2023). Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla ^−/− zebrafish model of Fabry disease. (ekstern lenke)
• Delaleu, Nicolas; Marti, Hans Peter; Strauss, Philipp et al. (2023). Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing. (ekstern lenke)
• Linhart, Aleš; Dostalova, Gabriela; Nicholls, Kathy et al. (2023). Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. (ekstern lenke)
• Braun, Fabian; Abed, Ahmed; Sellung, Dominik et al. (2023). Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. (ekstern lenke)
• Salvador, Cathrin Lytomt; Flemmen, Per Trygge Kjelland; Tøndel, Camilla et al. (2023). Renal function, sex and age influence purines and pyrimidines in urine and could lead to diagnostic misinterpretation. (ekstern lenke)
• Bansal, Amit; Trieu, Mai Chi; Mohn, Kristin Greve-Isdahl et al. (2023). Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. (ekstern lenke)
• Bichet, Daniel G; Hopkin, Robert J.; Aguiar, Patricio et al. (2023). Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study. (ekstern lenke)
• Lillås, Bjørn Steinar Demma; Tøndel, Camilla; Melsom, Toralf et al. (2023). Renal Functional Response-Association With Birth Weight and Kidney Volume. (ekstern lenke)
• Smerkous, David; Mauer, Michael; Tøndel, Camilla et al. (2023). Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases.. (ekstern lenke)
• Ertesvåg, Nina Urke; Xiao, Julie; Zhou, Fan et al. (2022). A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. (ekstern lenke)
• Syre, Heidi; Obreque, Marius Eduardo Brå; Dalen, Ingvild et al. (2022). The performances of three commercially available assays for the detection of SARS‐CoV‐2 antibodies at different time points following SARS‐CoV‐2 infection. (ekstern lenke)
• Elsaid, Hassan Osman Alhassan; Furriol, Jessica; Blomqvist, Maria et al. (2022). Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype. (ekstern lenke)
• Fjelltveit, Elisabeth Berg; Blomberg, Bjørn; Kuwelker, Kanika et al. (2022). Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. (ekstern lenke)
• Elsaid, Hassan Osman Alhassan; Tjeldnes, Håkon; Rivedal, Mariell Lossius et al. (2022). Gene Expression Analysis in gla-Mutant Zebrafish Reveals Enhanced Ca²⁺ Signaling Similar to Fabry Disease. (ekstern lenke)
• Gjerstad, Ann Christin; Skrunes, Rannveig; Tøndel, Camilla et al. (2022). Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up. (ekstern lenke)
• Hopkin, Robert J.; Cabrera, Gustavo; Jefferies, John et al. (2022). Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry registry. (ekstern lenke)
• Najafian, Behzad; Silvestroni, Aurelio; Sokolovskiy, Alexey et al. (2022). A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease. (ekstern lenke)
• Smeets, Nori JL; Teunissen, Esther MM; Velden, Kim van der et al. (2022). Glomerular filtration rate in critically ill neonates and children: creatinine-based estimations versus iohexol-based measurements. (ekstern lenke)
• Arrieta, Antonio C; Ang, Jocelyn Y; Espinosa, Claudia et al. (2021). Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. (ekstern lenke)
• Casabona, Giacomo; Habib, Ahsan; Povey, Michael et al. (2021). Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children. (ekstern lenke)
• Tøndel, Camilla; Marti, Hans Peter (2021). Cardiovascular changes in young renal failure patients. (ekstern lenke)
• Veen, Sanne van der; Körver, Simon; Hirsch, A et al. (2021). Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression. (ekstern lenke)
• Eide, Thea Tislevoll; Hufthammer, Karl Ove; Brun, Atle et al. (2021). Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination. (ekstern lenke)
• Lillås, Bjørn Steinar; Tøndel, Camilla; Assmus, Jörg et al. (2021). Low birthweight is associated with lower glomerular filtration rate in middle-aged mainly healthy women. (ekstern lenke)
• Moreno-Martinez, David; Aguiar, Patricio; Auray-Blais, Christiane et al. (2021). Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. (ekstern lenke)
• Kuwelker, Kanika; Zhou, Fan; Blomberg, Bjørn et al. (2021). Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. (ekstern lenke)
• Baka‐Ostrowska, Małgorzata; Bolong, David T.; Persu, Cristian et al. (2021). Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study. (ekstern lenke)
• Blomberg, Bjørn; Mohn, Kristin Greve-Isdahl; Brokstad, Karl Albert et al. (2021). Long COVID in a prospective cohort of home-isolated patients. (ekstern lenke)
• Trieu, Mai Chi; Bansal, Amit; Madsen, Anders et al. (2020). SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. (ekstern lenke)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2020). Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. (ekstern lenke)
• Mohn, Kristin Greve Isdahl; Brokstad, Karl Albert; Islam, Shahinul et al. (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. (ekstern lenke)
• Thorsteinsdottir, Hjørdis; Salvador, Cathrin Lytomt; Mjøen, Geir et al. (2020). Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation. (ekstern lenke)
• Lillås, Bjørn Steinar; Tøndel, Camilla; Gjerde, Anna et al. (2019). Measurement of renal functional response using iohexol clearance-A study of different outpatient procedures. (ekstern lenke)
• Ramaswami, Uma; Bichet, Daniel G; Clarke, Lorne et al. (2019). Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial. (ekstern lenke)
• Rittig, Søren; Baka-Ostrowska, Malgorzata; Tøndel, Camilla et al. (2019). The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. (ekstern lenke)
• Sandbye, Christiane Lerche; Shroff, Rukshana; Wan, Mandy et al. (2018). Effects of nutritional Vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease. (ekstern lenke)
• Salvador, Cathrin Lytomt; Tøndel, Camilla; Rowe, Alexander D. et al. (2018). Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. (ekstern lenke)
• Spada, Marco; Baron, Ralf; Elliott, Perry M. et al. (2018). The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. (ekstern lenke)
• Svarstad, Einar; Leh, Sabine Maria; Skrunes, Rannveig et al. (2017). Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits. (ekstern lenke)
• Eikrem, Øystein Solberg; Skrunes, Rannveig; Tøndel, Camilla et al. (2017). Pathomechanisms of renal Fabry disease. (ekstern lenke)
• Suntjens, Eefje B.; Dreschler, Wouter Albert; Hess-Erga, Jeanette et al. (2017). Hearing loss in children with Fabry disease. (ekstern lenke)
• Salvador, Cathrin Lytomt; Tøndel, Camilla; Rowe, Alexander D. et al. (2017). Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase–Associated Lipocalin in Children. (ekstern lenke)
• Skrunes, Rannveig; Tøndel, Camilla; Leh, Sabine Maria et al. (2017). Long-term dose-dependent agalsidase effects on kidney histology in fabry disease. (ekstern lenke)
• Tøndel, Camilla; Salvador, Cathrin Lytomt; Hufthammer, Karl Ove et al. (2017). Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. (ekstern lenke)
• Skrunes, Rannveig; Svarstad, Einar; Larsen, Kristin Kampevold et al. (2016). Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. (ekstern lenke)
• Tøndel, Camilla; Bolann, Bjørn Johan; Salvador, Cathrin Lytomt et al. (2016). Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. (ekstern lenke)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2016). One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. (ekstern lenke)
• Mohn, Kristin Greve Isdahl; Brokstad, Karl Albert; Pathirana, Rishi et al. (2016). Live attenuated influenza vaccine in children induces b-cell responses in tonsils. (ekstern lenke)
• Wijburg, Frits; Benichou, Bernard; Bichet, Daniel G et al. (2015). Characterization of early disease status in treatment-naive male paediatric patients with fabry disease enrolled in a randomized clinical trial. (ekstern lenke)
• Tøndel, Camilla; Kanai, Takahiro; Larsen, Kristin Kampevold et al. (2015). Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. (ekstern lenke)
• Salvador, Cathrin Lytomt; Tøndel, Camilla; Mørkrid, Lars et al. (2015). Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. (ekstern lenke)
• Mohn, Kristin Greve Isdahl; Bredholt, Geir; Brokstad, Karl Albert et al. (2015). Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. (ekstern lenke)
• Biegstraaten, Marieke; Arngrímsson, R; Barbey, F et al. (2015). Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. (ekstern lenke)
• Tol, Linda van der; Cassiman, David; Houge, Gunnar et al. (2014). Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. (ekstern lenke)
• Mauer, Michael; Glynn, Emily; Svarstad, Einar et al. (2014). Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. (ekstern lenke)
• Tol, Linda van der; Svarstad, Einar; Ortiz, Alberto et al. (2014). Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. (ekstern lenke)
• Tøndel, Camilla; Bostad, Leif; Larsen, Kristin Kampevold et al. (2013). Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. (ekstern lenke)
• Linthorst, Gabor E.; Burlina, Allessandro; Cecchi, Franco et al. (2012). Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. (ekstern lenke)
• Tøndel, Camilla; Vikse, Bjørn Egil; Bostad, Leif et al. (2012). Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. (ekstern lenke)
• Najafian, Behzad; Svarstad, Einar; Bostad, Leif et al. (2011). Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. (ekstern lenke)
• Guest, Julian F; Jenssen, Trond; Houge, Gunnar et al. (2010). Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. (ekstern lenke)
• Tøndel, Camilla; Ramaswami, Uma; Aakre, Kristin Moberg et al. (2010). Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. (ekstern lenke)
• Tøndel, Camilla; Ramaswami, Uma; Aakre, Kristin Moberg et al. (2009). Monitoring renal Function in Fabry children: comparisons of measured and creatinine-based estimated Glomerular Filtration Rate. (ekstern lenke)
• Aakre, Kristin M.; Tøndel, Camilla; Brun, Atle et al. (2009). The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. (ekstern lenke)
• Tøndel, Camilla; Bostad, Leif; Hirth, Asle et al. (2008). Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. (ekstern lenke)
• Svarstad, Einar; Bostad, Leif; Kaarbøe, Øyvind et al. (2005). Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. (ekstern lenke)
• Tøndel, Camilla; Lægreid, Liv Marie; Hirth, Asle et al. (2003). [Intravenous Enzyme Substitution Therapy in Children With Fabry's Disease]. (ekstern lenke)
• Juliusson, Petur Benedikt; Tøndel, Camilla; Aanderud, Sylvi et al. (2002). Behandling av Graves sykdom hos barn og unge. (ekstern lenke)

Intervju

• Tøndel, Camilla (2025). Vil ha tidlig pottetrening: – Vi lærer ungene å tisse på seg. (ekstern lenke)
• Tøndel, Camilla; Berg, Are Stuwitz (2024). Vaksine mot vannkopper. (ekstern lenke)
• Tøndel, Camilla (2024). Foreslår at alle barn skal få vaksine mot vannkopper fra neste år. (ekstern lenke)
• Tøndel, Camilla (2024). Evolving screening and diagnosis strategies in Fabry disease. (ekstern lenke)
• Cox, Rebecca Jane; Tøndel, Camilla; Spurkland, Anne et al. (2023). Bør alle norske barn vaksineres mot vannkopper?. (ekstern lenke)
• Tøndel, Camilla (2022). Nye behandlingsformer for Fabrys sykdom under utprøving. (ekstern lenke)
• Tøndel, Camilla (2022). Katrine (47) har meldt seg frivillig til å teste en ny, norsk vaksine. Håpet er at den skal beskytte lenger enn de man har hatt til nå. (ekstern lenke)
• Tøndel, Camilla (2022). Lovende resultater av mulig ny behandling av Fabry sykdom: – Stor praktisk betydning. (ekstern lenke)
• Tøndel, Camilla (2021). Her settes første dose av norskutviklet koronavaksine. (ekstern lenke)
• Tøndel, Camilla (2015). Har testet medisiner på 400 barn. (ekstern lenke)
• Tøndel, Camilla (2015). Kreft hos barn og betydning av klinisk utprøving hos barn. (ekstern lenke)
• Gunnes, Maria Winther; Tøndel, Camilla (2014). Kampen mot kreft. (ekstern lenke)
• Halvorsen, Thomas; Tøndel, Camilla (2014). Forskning på legemidler til barn må gjøres i Norge. (ekstern lenke)
• Tøndel, Camilla (2013). Forskning på medisiner til barn, Ekko. (ekstern lenke)
• Tøndel, Camilla; Svarstad, Einar (2013). Enzyme replacement in Fabry disease. (ekstern lenke)

Poster

• Hopkin, Robert; Hughes, Derralynn A.; Bernat, John et al. (2025). Evaluating the relationship between infusion-related reactions and anti-drug antibody status: Results from 111 patients with Fabry disease treated with pegunigalsidase alfa. (ekstern lenke)
• Bernat, John; Holida, Myrl; Waldek, Stephen et al. (2025). Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: Five-year interim results from the ongoing BRIGHT51 study. (ekstern lenke)
• Tøndel, Camilla; Pisani, Antonio; Bernat, John A. et al. (2024). Cross-Sectional Analysis of Organ Involvement and Biomarker Levels in Patients With and Without Antidrug Antibodies to Enzyme Replacement Therapies for Fabry Disease. (ekstern lenke)
• Bernat, John; Hughes, Derralynn A.; Linhart, Aleš et al. (2024). Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies. (ekstern lenke)
• Hughes, Derralynn A.; Bernat, John; Linhart, Aleš et al. (2024). Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by dosing regimens. (ekstern lenke)
• Mehta, Ankit; Wallace, Eric; Linhart, Aleš et al. (2024). Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by prior enzyme replacement therapy. (ekstern lenke)
• Wallace, Eric; Goker-Alpan, Ozlem; Holida, Myrl et al. (2023). First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study. (ekstern lenke)
• Smerkous, David; Mauer, Michael; Tøndel, Camilla et al. (2023). Development of an online cloud-based tool for automatic measurement of foot process width (FPW) using deep learning (DL): Applications in assessment of podocyte injury in Fabry disease (FD). (ekstern lenke)
• Bernat, John; Holida, Myrl; Longo, Nicola et al. (2023). Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study. (ekstern lenke)
• Najafian, Behzad; Nicholls, Kathleen; West, Michael L et al. (2023). The spectrum of podocyte injury in later onset (LO) variants of Fabry disease (FD). (ekstern lenke)
• Warnock, David G; Goker-Alpan, Ozlem; Bernat, John et al. (2023). Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program. (ekstern lenke)
• Salvador, Cathrin Lytomt; Flemmen, Per Tryggve Kjelland; Woldseth, Berit et al. (2023). Reduced renal function and other factors influence the measured level of glycosaminoglycans (GAGs) and could lead to diagnostic misinterpretation. (ekstern lenke)
• Tøndel, Camilla; Warnock, David G; Goker-Alpan, Ozlem et al. (2023). Pooled analysis of the effect of pegunigalsidase alfa on renal function: Data from 113 patients in the pegunigalsidase alfa clinical trial program. (ekstern lenke)
• Tøndel, Camilla; Wallace, Eric; Rocco, Rossana et al. (2022). Pharmacokinetic (PK) Results From a Phase 3 Trial to Evaluate Pegunigalsidase Alfa Every 4 Weeks (Q4W) in Patients (Pts) With Fabry Disease Previously Treated With Agalsidase Beta or Agalsidase Alfa. (ekstern lenke)
• Kopsidas, John; Hofstraat, Sanne; Salmanton-García, Jon et al. (2022). Capacity mapping and building for pediatric vaccine trials across Europe with VACCELERATE’s harmonized assessment tool. (ekstern lenke)
• Holida, Myrl; Bernat, John; Longo, Nicola et al. (2022). Safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Results from the phase 3, open-label, BRIGHT study. (ekstern lenke)
• Najafian, Behzad; Silvestroni, Aurelio; Sokolovskiy, Alexey et al. (2022). Globotriaosylceramide (GL3) accumulation in Fabry podocytes in female patients is progressive with age and associated with podocyte loss and proteinuria. (ekstern lenke)
• Bradley, John S; Makieieva, Natalia; Tøndel, Camilla et al. (2021). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-dose Clinical Trial. (ekstern lenke)
• Braun, Fabian; Abed, Ahmed; Woidy, Mathias et al. (2021). Synuclein Alpha Accumulation Drives Lysosomal Dysfunction in Fabry Podocytopathy. (ekstern lenke)
• Tøndel, Camilla; Linhart, Aleš; Dostalova, Gabriela et al. (2020). Switching from Agalsidase Alfa to Pegunigalsidase Alfa for Treating Fabry Disease: One Year of Treatment Data from Bridge, a Phase 3 Open-Label Study. (ekstern lenke)
• Eikrem, Øystein Solberg; Delaleu, Nicolas; Strauss, Philipp et al. (2020). Systems Analyses of Renal Fabry Transcriptome and Response to Enzyme Replacement Therapy (ERT) Identifies a Cross-Validated and Druggable ERT-Resistant Module. (ekstern lenke)
• Smeets, Nori JL; Teunissen, E; Teesselink, E et al. (2020). Diagnosis of AKI using Iohexol in critically ill children and neonates: preliminary results of the HERO study. (ekstern lenke)
• Lillås, Bjørn Steinar Demma; Tøndel, Camilla; Vikse, Bjørn Egil (2020). Low Birth Weigth Is Associated With Lower Measured Glomerular Filtration Rate In Adult Age. (ekstern lenke)
• Linhart, Aleš; Dostalova, Gabriela; Nicholls, Kathleen et al. (2020). Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study. (ekstern lenke)
• Linhart, Aleš; Nicholls, Kathy; West, Michael et al. (2019). Pegunigalsidase alfa for the treatment of Fabry disease - Phase III open label, switch over study from agalsidase alfa - Preliminary results. (ekstern lenke)
• Warnock, David G; Wallace, Eric; Schiffman, Raphael et al. (2019). Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa Phase III BALANCE study. (ekstern lenke)
• Holida, Myrl; Bernat, John; Longo, Nicola et al. (2019). Once every 4 weeks 2 mg/kg of pegunigalsidase alfa for treating Fabry disease- preliminary result of a phase 3 study. (ekstern lenke)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2019). Accumulation of Globotriaosylceramide in Podocytes (PC) in Fabry Nephropathy Is Associated with Progressive PC Loss. (ekstern lenke)
• Linhart, Aleš; Nicholls, Kathy; West, Michael et al. (2019). Prelimenary Results of the Fabry Disease Phase III Open Label Study of Switching from Agalsidase Alfa to Pegunigalsidase Alfa. (ekstern lenke)
• Holida, Myrl; Bernat, John; Longo, Nicola et al. (2019). New Regimen of Once Every 4 Weeks 2 mg/kg of Pedunigalsidase Alfa for Treating Fabry Disease - Prelimenary Results of a Phase 3 Study. (ekstern lenke)
• Svarstad, Einar; Skrunes, Rannveig; Davidsen, Einar Skulstad et al. (2019). Clinical Consequences of Paired Cardiac and Kidney Biopsies in a Treatment Naive Female Fabry Patient with a Classical Mutation and Minor Clnical Symptoms. (ekstern lenke)
• Lillås, Bjørn Steinar Demma; Tøndel, Camilla; Gjerde, Anna et al. (2019). Measurement of renal functional response using iohexol clearance. (ekstern lenke)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2018). Podocyte structural parameters predict glomerular filtration rate (GFR) loss in male patients with classic Fabry disease. (ekstern lenke)
• Eikrem, Øystein Solberg; Strauss, Philipp; Sekulic, Miroslav et al. (2018). Fabry nephropathy: Transcriptome sequencing of microdissected renal compartments from archival kidney biopsies at baseline, and after 5 & 10 years of enzyme replacement therapy. (ekstern lenke)
• Wanner, Christoph; Elliot, PM; Formin, V et al. (2018). KIDNEY-SPECIFIC THERAPEUTIC GOALS FOR FABRY DISEASE BASED ON EUROPEAN EXPERT CONSENSUS RECOMMENDATIONS AND SYSTEMATIC REVIEW OF PUBLISHED EVIDENCE. (ekstern lenke)
• Tøndel, Camilla; Salvador, Cathrin Lytomt; Hufthammer, Karl Ove et al. (2018). IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR. (ekstern lenke)
• Eide, Thea Tislevoll; Brun, Atle; Brackman, Damien et al. (2018). SINGLE INTRAVENOUS ACCESS FOR MEASUREMENT OF GLOMERULAR FILTRATION RATE IN CHILDREN AFTER MARKER INJECTION. (ekstern lenke)
• Svarstad, Einar; Skrunes, Rannveig; Leh, Sabine Maria et al. (2017). Simplified Clinical Pre-histologic Scoring Method of Kidney Biopsies in Fabry Disease. (ekstern lenke)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2017). Podocyte globotriaosylceramide (GL-3) content strongly impacts age-dependent podocyte loss in ERT-naïve male Fabry patients. (ekstern lenke)
• Ramaswami, Uma; Wijburg, Frits; Bichet, Daniel G et al. (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells. (ekstern lenke)
• Ramaswami, Uma; Wijburg, Frits; Bichet, Daniel G et al. (2017). A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from superficial skin capillary endothelium. (ekstern lenke)
• Tøndel, Camilla; Salvador, Cathrin Lytomt; Hufthammer, Karl Ove et al. (2017). Single-point iohexol plasma clearance in children: validation of multiple formulas and sampling times. (ekstern lenke)
• Chang, Fu-Pang; Mauer, Michael; Sokolovskiy, Alexey et al. (2016). Differential response of glomerular parietal epithelial cells and podocytes to enzyme replacement therapy in Fabry nephropathy. (ekstern lenke)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2016). Podocyte Hypertrophy and Globotriaosylceramide (GL-3) Accumulation Are Strong Predictors of Podocyte Loss in Enzyme Replacement Therapy Naïve Male Patients with Fabry Disease. (ekstern lenke)
• Salvador, Cathrin Lytomt; Rowe, Alexander D.; Bjerre, Anna Kristina et al. (2016). Glomerular filtration rate (GFR) strongly influences guanidinoacetic acid (GAA) in plasma and urine. (ekstern lenke)
• Thorsteinsdottir, Hjørdis; Salvador, Cathrin Lytomt; Tøndel, Camilla et al. (2016). GDF-15 in plasma and urine as a marker of kidney function in children. (ekstern lenke)
• Najafian, Behzad; Tøndel, Camilla; Svarstad, Einar et al. (2015). Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype. (ekstern lenke)
• Skrunes, Rannveig; Tøndel, Camilla; Larsen, Kristin Kampevold et al. (2015). LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) BENEFITS THE GLOMERULI MORE THAN THE VASCULATURE IN YOUNGER FABRY NEPHROPATHY. (ekstern lenke)
• Skrunes, Rannveig; Svarstad, Einar; Larsen, Kristin Kampevold et al. (2015). DIFFERENTIAL KIDNEY EFFECTS OF HIGH AND LOW ENZYME DOSE IN MALE SIBLINGS TREATED FOR 13 YEARS. (ekstern lenke)
• Skrunes, Rannveig; Larsen, Kristin Kampevold; Leh, Sabine Maria et al. (2015). FABRY DISEASE DIAGNOSED IN LIVING DONOR KIDNEY TRANSPLANT BIOPSY. (ekstern lenke)
• Tøndel, Camilla; Kanai, Takahiro; Larsen, Kristin Kampevold et al. (2014). Five Children with Fabry Disease and Significant Tissue Damage in Renal Biopsies Despite Normal Clinical Renal Parameters. (ekstern lenke)
• Tol, Linda van der; Vogt, L; Florquin, S et al. (2014). Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease. (ekstern lenke)
• Najafian, Behzad; Mauer, Michael; Svarstad, Einar et al. (2014). Enzyme Replacement Therapy (ERT) in Fabry Disease (FD) Reduces Podocyte (PC) Globotriaosylceramide (GL3) Content within a Year (yr). (ekstern lenke)
• Tøndel, Camilla; Larsen, Kristin Kampevold; Skrunes, Rannveig et al. (2014). Renal Biopsies after 6-11 Years of Enzyme Replacement Therapy in 9 Young Classic Fabry Disease Patients. (ekstern lenke)
• Skrunes, Rannveig; Larsen, Kristin Kampevold; Svarstad, Einar et al. (2014). Fabry nephropathy (FN) outcome and the impact of diagnostic kidney biopsies after 10 years enzyme replacement therapy (ERT). (ekstern lenke)
• Tøndel, Camilla; Bolann, Bjørn Johan; Salvador, Cathrin Lytomt et al. (2013). Glomerular filtration rate (GFR) measured by iohexolclearance in children; how many sample points are necessary?. (ekstern lenke)
• Salvador, Cathrin Lytomt; Tøndel, Camilla; Mørkrid, Lars et al. (2013). Glomerular Filtration Rate (GFR) measured by Iohexol Clearance in Children; a comparison between venous samples and dried spots. (ekstern lenke)
• Tøndel, Camilla; Svarstad, Einar; Bostad, Leif (2009). Renal follow-up biopsies in young male Fabry patients on enzyme replacement therapy. (ekstern lenke)
• Tøndel, Camilla; Aakre, Kristin M.; Brun, Atle et al. (2008). Formula GFR overestimates Renal Function in Children and Adult Males with Fabry Disease and Stage 1-2 CKD. (ekstern lenke)
• Tøndel, Camilla; Vikse, Bjørn Egil; Iversen, Bjarne Magnus et al. (2008). Renal biopsies in children in Norway 1988-2005: clinical variables, complications and prognosis. (ekstern lenke)
• Tøndel, Camilla; Bertelsen, AK; Bostad, Leif et al. (2008). Fabry disease: Unusual symptoms in two male children treated with lamotrigine and fabrazyme, respectively. (ekstern lenke)

Doktorgradsavhandling

• Lillås, Bjørn Steinar Demma; Tøndel, Camilla; Vikse, Bjørn Egil et al. (2024). Impact of birth weight on kidney health in middle-aged adults : Results from the Haugesund Low Birth Weight Study. (ekstern lenke)
• Strauss, Philipp; Eikrem, Øystein Solberg; Marti, Hans Peter et al. (2023). From archival tissues to systems biology: Using transcriptomics to investigate the progression of kidney disease. (ekstern lenke)
• Salvador, Cathrin Lytomt; Mørkrid, Lars; Bergan, Stein et al. (2020). Estimation and measurement of glomerular filtration rate in children. (ekstern lenke)
• Skrunes, Rannveig; Tøndel, Camilla (2017). Hereditary renal disease in the Norwegian population, with a focus on Fabry disease. (ekstern lenke)
• Tøndel, Camilla (2013). Markers of nephropathy in young Fabry disease patients; role of kidney biopsies and functional measurements. (ekstern lenke)

Leserinnlegg

• Lillås, Bjørn Steinar Demma; Tøndel, Camilla; Melsom, Toralf et al. (2023). Response to Birth Weight and Renal Functional Reserve in Adults. (ekstern lenke)
• Bratlie, Sigrid; Alsheikh, Muath K; Brautaset, Trygve et al. (2023). Mer faglighet fra naturbevegelsen, takk. (ekstern lenke)
• Bertelsen, Anne Kjørsvik; Tøndel, Camilla; Krohn, Jørgen Gitlesen et al. (2013). Small fibre neuropathy in Fabry disease. (ekstern lenke)
• Houge, Gunnar; Tøndel, Camilla; Kaarbøe, Øyvind et al. (2011). Fabry or not Fabry – a question of ascertainment. (ekstern lenke)

Kronikk

• Bratlie, Sigrid; Tøndel, Camilla; Alsheikh, Muath K et al. (2023). GMO-regler må ikke få stoppe utviklingen av avanserte terapier. (ekstern lenke)
• Gamlund, Espen; Alsheikh, Muath K; Bratlie, Sigrid et al. (2023). Uetisk å la være å satse på genteknologi. (ekstern lenke)
• Bratlie, Sigrid; Holst-Jensen, Arne; Alsheikh, Muath K et al. (2023). På tide å åpne for genteknologi i norsk matproduksjon. (ekstern lenke)

Rapport

• Wargelius, Anna; Alsheikh, Muath K; Gamlund, Espen et al. (2023). Genteknologi i en bærekraftig fremtid. (ekstern lenke)

Vitenskapelig oversiktsartikkel/review

• Burlina, Allesandro; Brand, Eva; Hughes, Derralynn A. et al. (2023). An expert consensus on the recommendations for the use of biomarkers in Fabry disease. (ekstern lenke)
• Tøndel, Camilla; Thurberg, Beth L.; DasMahapatra, Pronabesh et al. (2022). Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. (ekstern lenke)
• Wanner, Christoph; Arad, Michael; Baron, Ralf et al. (2018). European expert consensus statement on therapeutic goals in Fabry disease. (ekstern lenke)

Vitenskapelig foredrag

• Tøndel, Camilla; Riisnes, Idunn; Leh, Sabine et al. (2021). Cleared Podocytes and Normal Kidney Function in Classical Fabry Males 15 Years After Start of Enzyme Replacement Therapy at Young Age. (ekstern lenke)
• Bansal, Amit; Trieu, Mai Chi; Madsen, Anders et al. (2020). Low infection and seroconversion rates in frontline healthcare workers during the peak of the Coronavirus disease 2019 pandemic in Bergen, Norway. (ekstern lenke)
• Bansal, Amit; Trieu, Mai Chi; Madsen, Anders et al. (2020). SARS-COV-2-Specific neutralising antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. (ekstern lenke)
• Bansal, Amit; Trieu, Mai Chi; Madsen, Anders et al. (2020). Antibody responses to SARS-CoV-2 virus in Norwegian health-care workers: an observational prospective cohort study. (ekstern lenke)
• Strauss, Philipp; Eikrem, Øystein Solberg; Tøndel, Camilla et al. (2019). Fabry Nephropathy: First mRNA-seq Findings from Kidney Biopsies Before and After Enzyme Replacement Therapy. (ekstern lenke)
• Mohn, Kristin Greve Isdahl; Cox, Rebecca Jane; Zhou, Fan et al. (2015). Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.. (ekstern lenke)
• Tøndel, Camilla; Svarstad, Einar (2013). Podocytes: Therapeutic Target in Fabry Disease?. (ekstern lenke)
• Tøndel, Camilla; Bostad, Leif; Svarstad, Einar (2010). 5 YEARS FOLLOW-UP RENAL BIOPSIES IN PAEDIATRIC AND ADULT FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. (ekstern lenke)
• Haugen, Olav H.; Tøndel, Camilla; Svarstad, Einar (2009). Corneal changes in Fabry's disease. (ekstern lenke)

Errata

• Tøndel, Camilla; Bolann, Bjørn Johan; Salvador, Cathrin Lytomt et al. (2016). Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times (Pediatric Nephrology, (2017), 32, 2, (311-320), 10.1007/s00467-016-3436-z). (ekstern lenke)

Programdeltagelse

• Tøndel, Camilla (2015). Liv og død-serien; Legemiddelutprøving hos barn. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin

Filter - Nasjonalt vitenarkiv

PubMed

ResearchGate